Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women.
Despite the widespread use of the C21 progestin medroxyprogesterone acetate (MPA) in hormone replacement therapy and gynecological practice, its effects on bone density are uncertain, with contradictory reports in the literature. We have examined the short term changes in bone density at the lumbar spine (a predominantly trabecular site) and the femoral neck (a predominantly cortical site) in 13 premanopausal women prescribed high dose MPA (50 mg/day) for gynecological disorders and in 12 control subjects. Compared to basal values, lumbar spine bone mineral density (measured by dual energy x-ray absorptiometry) fell progressively by a mean 2.4% at 6 months and 4.1% at 12 months (both P < 0.01); in five subjects who continued the drug, it had fallen by a mean 5.9% at 20 months (P < 0.002). The spinal bone loss in the MPA users was significantly greater than that in controls (P < 0.005 at 6 months; P < 0.01 at 12 months) and occurred despite a significant gain in body weight in the women using MPA (median, 3.5 kg at 6 months; P < 0.01). In four subjects in whom bone density was measured 6 months after cessation of MPA, spinal bone density showed significant recovery (mean increment, 2.8%; P < 0.025). Femoral neck bone density measurements did not differ between the groups. MPA induced amenorrhea in all subjects who continued with it beyond 6 months, and the amenorrheic subjects were estrogen deficient (median plasma estradiol, 70 pmol/L). We conclude that, when given in doses sufficient to induce hypogonadism, MPA use is associated with significant early loss of trabecular bone, which is probably the consequence of estrogen deficiency.
Cundy
T
T
Department of Medicine, University of Auckland Medical School, New Zealand.
Farquhar
C M
CM
Cornish
J
J
Reid
I R
IR
D000284:Administration, Oral; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D005272:Femur Neck / Q000187:drug effects; D006801:Humans; D008161:Lumbosacral Region; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000494:pharmacology; D008875:Middle Aged; D017697:Premenopause; D013131:Spine / Q000187:drug effects; D013997:Time Factors
D004958:Estradiol; D017258:Medroxyprogesterone Acetate